Insider Trading Activity in: CASI Pharmaceuticals, Inc. $CASI

hand-982049_1920

CASI Pharmaceuticals, Inc. (CASI) insider have most recently took part in a trading activity. On Sep 19, 2017 He Wei-wu, Director bought 207,502 shares having total worth of $363,129 at the price of $1.75 per share, following the transaction a total of 2,860,204 shares owned by He Wei-wu. Before this latest buy, He Wei-wu purchased CASI at 2 other times during the past twelve months, for a total investment of $26.47M at an average of $1.26 per share.

The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 buy trades. Furthermore, over the past 12 months , the stock was traded 3 times by insiders. an employee of the company was the buyer in 3 instances.

Time Frame Number of Insider Buy Number of Insider Sell Stock Price Change(%)
3 Month 1 0 70.37%
12 Month 3 0 40.46%

Shares of CASI Pharmaceuticals, Inc. (CASI) traded down 1.6% on Sep 19, 2017, hitting $1.84. 374,883 shares of the company’s stock traded hands. CASI Pharmaceuticals, Inc. has a 52 week low of $0.84 and a 52 week high of $1.87. The company’s market cap is $0 million.

CASI Pharmaceuticals, Inc. (CASI) last announced its earnings results on Aug 14, 2017. The company reported -0.04 earnings per share (EPS) for the quarter. During the same quarter in the previous year, the company posted -0.08 earnings per share.

2017-08-14 2017-05-15 2017-03-31 2016-11-14 2016-08-15 2016-05-13 2016-03-28 2015-11-13 2015-08-14 2015-05-15
earnings per share -0.04 -0.03 -0.05 -0.03 -0.08 -0.04 -0.05 -0.07 -0.06 -0.06
Revenue(M) 0 0 0 0 0 0 0 0 23.99 0.02

EntreMed, Inc., is incorporated in Delaware. It is a clinical-stage pharmaceutical company employing drug development mainly in the United States and China to develop innovative targeted therapeutics designed to treat cancer and other diseases. In 2012, the Company refocused its clinical and regulatory strategy to leverage resources in China and to conduct clinical and regulatory activities in both China and US/Canada in order to accelerate delivery of clinical data and to reduce costs of clinical trials. Its lead drug candidate is ENMD-2076, a selective Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which it will continue to develop with approval by the United States Food and Drug Administration including global trials with sites in China, and in parallel shall develop locally under the China State and Food Drug Administration. The Company’s market focus includes developed countries, and also in particular. Its other product candidates in the pipeline include 2-methoxyestrdiol (2ME2) for autoimmune diseases for which it has an approved Investigational New Drug Application (IND) in rheumatoid arthritis treatment, and MKC-1, programs which it owns or have exclusive license to. It competes with many specialized biopharmaceutical firms, as well as a growing number of large pharmaceutical companies. In the United States, the FDA regulates product candidates currently being developed as drugs or biologics. New drugs are subject to regulation under the Federal Food, Drug, and Cosmetic Act (FFDCA), and biological products, in addition to being subject to certain provisions of that Act, are regulated under the Public Health Service Act (PHSA).

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.